Psoriasis Patients with Specific HLA-Cw Alleles and Lower Plasma IL-17 Level Show Improved Response to Topical Lindioil Treatment

Overview

Journal Pharmgenomics Pers Med

Publisher Dove Medical Press

Date 2022 May 20

PMID 35592551

Authors

Yin-Ku Lin

Ching-Ya Wang

Yu-Huei Huang

Ya-Ching Chang

Chun-Bing Chen

Chuang-Wei Wang

Rosaline Chung-Yee Hui

Wen-Hung Chung

Affiliations

Soon will be listed here.

Abstract

Purpose: Lindioil, a medicine refined from indigo naturalis (a herb used in Chinese medicine), is effective in treating severe psoriasis; however, responses vary across individual patients. We aim to investigate genetic predispositions associated with treatment response to topical Lindioil among patients with psoriasis and correlations with plasma cytokine patterns.

Patients And Methods: We enrolled 72 psoriasis patients treated with Lindioil ointment and analyzed the human leukocyte antigen class C () genotypes and plasma cytokine expression patterns. We developed regression models of treatment response, defined as Psoriasis Area and Severity Index (PASI) 75, to examine correlations among HLA-Cw alleles, cytokine levels, and treatment response to Lindioil.

Results: Patients harboring were significantly more likely to respond to Lindioil ( = 0.02, odds ratio [OR]: 6.88), whereas Lindoil was ineffective in those harboring ( = 0.01, OR: 0.28). Patients who were -positive or -negative had better PASI scores and body surface area (BSA) improvement (73.3% vs 44.4%, <0.001) following an 8-week treatment period. Psoriasis patients achieving PASI 75 after 8 weeks presented with lower baseline plasma interleukin-17 (IL-17) levels than those who did not achieve PASI 75 (PASI 75: 11.28 pg/mL vs PASI <75: 15.82 pg/mL, = 0.05).

Conclusion: Our findings suggest that the presence of the or alleles and plasma IL-17 levels are predictive markers of treatment response to Lindioil ointment in patients with psoriasis.

Citing Articles

The new era of immune skin diseases: Exploring advances in basic research and clinical translations.

Zhang B, Mei X, Zhao M, Lu Q J Transl Autoimmun. 2024; 8:100232.

PMID: 39022635 PMC: 11252396. DOI: 10.1016/j.jtauto.2024.100232.

Pharmacogenomics on the Treatment Response in Patients with Psoriasis: An Updated Review.

Wang C, Wang C, Chen C, Chen W, Chang Y, Hui R Int J Mol Sci. 2023; 24(8).

PMID: 37108492 PMC: 10138383. DOI: 10.3390/ijms24087329.

References

Lin Y, Chen H, Leu Y, Yang Y, Fang Y, Pang J . Indigo naturalis upregulates claudin-1 expression in human keratinocytes and psoriatic lesions. J Ethnopharmacol. 2012; 145(2):614-20. DOI: 10.1016/j.jep.2012.11.044. View

Nakagawa H, Asahina A, Akazaki S, Tokunaga K, Matsuki K, Ishibashi Y . Association of Cw11 in Japanese patients with psoriasis vulgaris. Tissue Antigens. 1990; 36(5):241-2. DOI: 10.1111/j.1399-0039.1990.tb01835.x. View

Dand N, Duckworth M, Baudry D, Russell A, Curtis C, Lee S . HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis. J Allergy Clin Immunol. 2018; 143(6):2120-2130. DOI: 10.1016/j.jaci.2018.11.038. View

Chang H, Pang J, Yang S, Hung C, Chiang C, Lin T . Inhibitory effect of indigo naturalis on tumor necrosis factor-α-induced vascular cell adhesion molecule-1 expression in human umbilical vein endothelial cells. Molecules. 2010; 15(9):6423-35. PMC: 6257747. DOI: 10.3390/molecules15096423. View

Chen L, Tsai T . HLA-Cw6 and psoriasis. Br J Dermatol. 2017; 178(4):854-862. DOI: 10.1111/bjd.16083. View

Indhumathi S, Rajappa M, Chandrashekar L, Ananthanarayanan P, Thappa D, Negi V . Pharmacogenetic markers to predict the clinical response to methotrexate in south Indian Tamil patients with psoriasis. Eur J Clin Pharmacol. 2017; 73(8):965-971. DOI: 10.1007/s00228-017-2255-x. View

Perera G, Di Meglio P, Nestle F . Psoriasis. Annu Rev Pathol. 2011; 7:385-422. DOI: 10.1146/annurev-pathol-011811-132448. View

Lin Y, Yen H, Wong W, Yang S, Pang J . Successful treatment of pediatric psoriasis with Indigo naturalis composite ointment. Pediatr Dermatol. 2006; 23(5):507-10. DOI: 10.1111/j.1525-1470.2006.00295.x. View

Lin Y, See L, Huang Y, Chang Y, Tsou T, Leu Y . Comparison of refined and crude indigo naturalis ointment in treating psoriasis: randomized, observer-blind, controlled, intrapatient trial. Arch Dermatol. 2012; 148(3):397-400. DOI: 10.1001/archdermatol.2011.1091. View

10.

Bungsu I, Kifli N, Ahmad S, Ghani H, Cunningham A . Herbal Plants: The Role of AhR in Mediating Immunomodulation. Front Immunol. 2021; 12:697663. PMC: 8264659. DOI: 10.3389/fimmu.2021.697663. View

11.

Gallo E, Cabaleiro T, Roman M, Solano-Lopez G, Abad-Santos F, Garcia-Diez A . The relationship between tumour necrosis factor (TNF)-α promoter and IL12B/IL-23R genes polymorphisms and the efficacy of anti-TNF-α therapy in psoriasis: a case-control study. Br J Dermatol. 2013; 169(4):819-29. DOI: 10.1111/bjd.12425. View

12.

Edson-Heredia E, Sterling K, Alatorre C, Cuyun Carter G, Paczkowski R, Zarotsky V . Heterogeneity of response to biologic treatment: perspective for psoriasis. J Invest Dermatol. 2013; 134(1):18-23. DOI: 10.1038/jid.2013.326. View

13.

Tadros A, Vergou T, Stratigos A, Tzavara C, Hletsos M, Katsambas A . Psoriasis: is it the tip of the iceberg for the quality of life of patients and their families?. J Eur Acad Dermatol Venereol. 2011; 25(11):1282-7. DOI: 10.1111/j.1468-3083.2010.03965.x. View

14.

Cai M, Huang H, Ran D, Zheng X, Wen L, Zhu Z . HLA-C*01:02 and HLA-A*02:07 Confer Risk Specific for Psoriatic Patients in Southern China. J Invest Dermatol. 2019; 139(9):2045-2048.e4. DOI: 10.1016/j.jid.2019.02.027. View

15.

Hsieh W, Lin Y, Tsai C, Wang T, Chen T, Pang J . Indirubin, an acting component of indigo naturalis, inhibits EGFR activation and EGF-induced CDC25B gene expression in epidermal keratinocytes. J Dermatol Sci. 2012; 67(2):140-6. DOI: 10.1016/j.jdermsci.2012.05.008. View

16.

Lin Y, Leu Y, Yang S, Chen H, Wang C, Pang J . Anti-psoriatic effects of indigo naturalis on the proliferation and differentiation of keratinocytes with indirubin as the active component. J Dermatol Sci. 2009; 54(3):168-74. DOI: 10.1016/j.jdermsci.2009.02.007. View

17.

Cheng H, Kuo Y, Chang C, Chang C, Fang W, Chang C . The anti-TH17 polarization effect of Indigo naturalis and tryptanthrin by differentially inhibiting cytokine expression. J Ethnopharmacol. 2020; 255:112760. DOI: 10.1016/j.jep.2020.112760. View

18.

Griffiths C, Barker J . Pathogenesis and clinical features of psoriasis. Lancet. 2007; 370(9583):263-271. DOI: 10.1016/S0140-6736(07)61128-3. View

19.

Lin Y, Wong W, Chang Y, Chang C, Tsay P, Chang S . The efficacy and safety of topically applied indigo naturalis ointment in patients with plaque-type psoriasis. Dermatology. 2007; 214(2):155-61. DOI: 10.1159/000098576. View

20.

Borroni R, Costanzo A . HLA-C*06 and psoriasis: susceptibility, phenotype, course and response to treatment. Br J Dermatol. 2018; 178(4):825. DOI: 10.1111/bjd.16412. View